Winnipeg, MB - February 7, 2024 – Cytophage Technologies Ltd. (“Cytophage” or the “Company”)
(TSXV:CYTO) (formerly Cuspis Capital III Ltd. (“Cuspis”) (TSXV:CIII.P)) is pleased to announce that it has received its final bulletin from the TSX Venture Exchange Inc. (the “TSXV”), and is scheduled to commence trading on February 9th, 2024.
The decision to go-public represents a significant milestone for Cytophage as it positions itself for growth, enhanced visibility, and increased potential commercial opportunities. The TSXV, known for its dynamic and innovative market, provides Cytophage with a platform to access a broader investor base and further solidify its position as an integral contributor in the human and animal health sector.
“We are thrilled to announce this important step in the evolution of Cytophage Technologies,” said Dr.
Steven Theriault, CEO/Founder of Cytophage. “Becoming a publicly traded company on the TSX Venture Exchange not only reflects the hard work and dedication of our team but also demonstrates our commitment to advancing our phage products through innovation and strategic growth initiatives.” Dr. Theriault added, “2024 is looking bright for the Company as we expand our market reach for our agricultural products and venture into human health applications.” The Company’s listing on the TSXV is expected to increase liquidity for existing shareholders while providing a transparent and regulated platform for investors.
“On behalf of my Cuspis partners and shareholders, I extend enthusiastic congratulations to Cytophage on successfully transitioning to a public company (CYTO) through the completion of this transaction with Cuspis III.” said William Ollerhead, former CEO of Cuspis and current director of Cytophage. “This is a pivotal step in the growth and evolution of Cytophage and represents an opportunity to broaden awareness and investor interest in the pioneering technology Cytophage is commercializing. The concerning rise of antimicrobial resistance, and the diminishing effectiveness of antibiotics is increasingly the subject of news stories and global healthcare discourse. We believe that the innovative and novel initiatives being undertaken by Cytophage, fueled by transformative science, to counter these intensifying challenges, will gain increasing attention. I am genuinely optimistic about the positive impact Cytophage can make on addressing these concerns.”
Cytophage is globally recognized for its innovative work with bacteriophages. The Company’s commitment to excellence, innovation, and sustainability has garnered recognition within the industry, making it an attractive investment opportunity for a wide range of investors.
Market Maker Agreement
Cytophage also announces that it has engaged Integral Wealth Securities Limited (“Integral”) to provide services as a market maker in compliance with the policies and guidelines of the TSXV and other applicable legislation. Under the agreement, Integral will receive a fee of C$6,000 plus applicable taxes per month. The initial term of the agreement is six (6) months from the date of execution.
For more information about Cytophage Technologies Ltd. and its listing on the TSXV, please visit
https://cytophage.com/news/
For media inquiries, kindly reach out to:
Heather Medwick
President
heather@cytophage.com
431 388 8873
About Cytophage
Cytophage is a pioneering biotechnology company dedicated to bacteriophage research, product
development and commercialization. Committed to addressing the global challenge of antibiotic
resistance, Cytophage advances innovative therapies that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health, and food security.
Source: Cytophage